STE•Steris reported fiscal second-quarter adjusted EPS of $2.94, beating the $2.68 analyst consensus, as revenue rose 9% year over year to an unspecified amount. It raised its fiscal 2027 adjusted EPS outlook to $11.35-$11.55 from $11.10-$11.30.
Steris said fiscal second-quarter revenue rose 9% year over year, including 8% organic growth. Adjusted EPS was $2.94, above the $2.68 consensus, while reported EPS was $2.19.
The company raised its fiscal 2027 adjusted EPS outlook to $11.35-$11.55 from $11.10-$11.30. It expects fiscal 2027 revenue growth of 7%-8% as reported and 6%-7% organic.
Life Sciences segment revenue increased 18%, led by 53% growth in capital equipment and higher consumables and service revenue. Tariff refunds provided a $20 million pretax benefit to quarterly results.
